Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Tang Website

Binwu Tang, Ph.D.

Portait Photo of Binwu Tang
Laboratory of Cancer Biology and Genetics
Cancer Biology of TGF-beta Section
Staff Scientist
Center for Cancer Research
National Cancer Institute
Building 37, Room 4032
Bethesda, MD 20892
Phone:  
301-496-8344
Fax:  
301-496-8395
E-Mail:  
tangb@mail.nih.gov

Biography

Dr. Binwu Tang graduated from Beijing Medical University. She received her Ph.D. degree in Pharmacology from Georgetown University Graduate School. From 1996 to 2004, Dr. Tang worked at Lab of Cell Regulation and Carcinogenesis, National Cancer Institute in Bethesda, MD as postdoctoral fellow and research fellow. She currently works with Dr. Lalage Wakefield in Laboratory of Cancer Biology and Genetics in NCI as a staff scientist. Dr. Tang was one of the recipients for NCI Director Research Innovation Award in 2007.

Research

Dr. Tang's major research interest is focused on understanding molecular mechanisms the dual role of TGF-beta in breast cancer. Dr. Tang formally tested the hypothesis that TGF-beta can switch from tumor suppressor to prometastatic factor during the course of carcinogenic progression within a given cell lineage. We used a xenograft model system of breast cancer progression, based on the MCF10A human breast epithelial line and transformed derivatives. By transducing these cells with a dominant negative form of the TGF-beta receptor and testing for tumorigenicity in nude mice, we have determined the dominant role played by the endogenous TGF-beta system at the various different stages. We have shown that decreased TGF-beta responsiveness alone cannot initiate tumorigenesis, but that it can cooperate with an initiating oncogenic lesion to make a premalignant breast cell tumorigenic and a low-grade tumorigenic line more aggressively tumorigenic. However, in a high-grade tumorigenic cell line, reduced TGF-beta responsiveness has no effect on primary tumorigenesis, but significantly reduces metastatic efficiency. Our results demonstrate a causal role for loss of TGF-beta response in promoting breast cancer progression up to the stage of advanced, histologically aggressive, but non-metastatic disease, and suggest that at that point TGF-beta switches from tumor suppressor to pro-metastatic factor. Recently, we showed that endogenous TGF-beta has the potential to suppress tumorigenesis through a novel mechanism, involving effects at two distinct levels in the hierarchy of cellular progeny that make up the epithelial component of the tumor. First, TGF-beta reduces the size of the putative cancer stem or early progenitor cell population, and second it promotes differentiation of a more committed, but highly proliferative, progenitor cell population to an intrinsically less proliferative state. We further show that reduced expression of the type II TGF-beta receptor correlates with loss of luminal differentiation in a clinical breast cancer cohort, suggesting that this mechanism may be clinically relevant. At a molecular level, the induction of differentiation by TGF-beta involves down-regulation of Id1, and forced overexpression of Id1 can promote tumorigenesis despite persistence of the antiproliferative effect of TGF-beta. These data suggest new roles for the TGF-beta pathway in regulating tumor cell dynamics that are independent of direct effects on proliferation.

This page was last updated on 3/5/2013.